EBV and post-transplant lymphoproliferative disorder: a complex relationship

淋巴增殖性病變 美罗华 淋巴瘤 医学 恶性肿瘤 背景(考古学) 弥漫性大B细胞淋巴瘤 爱泼斯坦-巴尔病毒 免疫学 肿瘤科 病理 病毒 生物 古生物学
作者
Nader Kim El‐Mallawany,Rayne H. Rouce
出处
期刊:Hematology [American Society of Hematology]
卷期号:2024 (1): 728-735
标识
DOI:10.1182/hematology.2024000583
摘要

Abstract Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous category of disease entities occurring in the context of iatrogenic immune suppression. Epstein-Barr virus (EBV)–driven B-cell lymphoproliferation represents the prototype of quintessential PTLD, which includes a range of histologies named nondestructive, polymorphic, and monomorphic EBV+ diffuse large B-cell lymphoma (DLBCL) PTLD. While EBV is associated with the majority of PTLD cases, other drivers of lymphoid neoplasia and lymphoma transformation can occur—with or without EBV as a codriver—thus underlining its vast heterogeneity. In this review, we discuss the evolution in contemporary PTLD nomenclature and its emphasis on more precise subcategorization, with a focus on solid organ transplants in children, adolescents, and young adults. We highlight the fact that patients with quintessential EBV-associated PTLD—including those with monomorphic DLBCL—can be cured with low-intensity therapeutic approaches such as reduction in immune suppression, surgical resection, rituximab monotherapy, or rituximab plus low-dose chemotherapy. There is, though, a subset of patients (approximately 30%-40%) with quintessential PTLD that remains refractory to lower-intensity approaches, for whom intensive, lymphoma-specific chemotherapy regimens are required. Other forms of monomorphic PTLD, which are as diverse as the spectrum of defined lymphoma entities that also occur in immunocompetent patients, are rarely cured with lower-intensity therapies and appear to be better categorized as posttransplant lymphomas. These distinct scenarios represent the variations in lymphoid pathology that make up a conceptual framework for PTLD consisting of lymphoid hyperplasia, neoplasia, and malignancy. This framework serves as the basis to inform risk stratification and determination of evidence-based treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
vlcx完成签到,获得积分10
1秒前
Judy完成签到 ,获得积分0
2秒前
玲丫头发布了新的文献求助10
3秒前
4秒前
Le完成签到,获得积分10
4秒前
4秒前
刘佳美发布了新的文献求助10
5秒前
李青梅完成签到,获得积分10
6秒前
6秒前
gui完成签到,获得积分10
7秒前
Le发布了新的文献求助30
7秒前
8秒前
迷你的柜子完成签到,获得积分10
8秒前
借一颗糖发布了新的文献求助30
9秒前
自然战斗机完成签到,获得积分20
10秒前
AE发布了新的文献求助10
10秒前
Owen应助Lixuer采纳,获得10
12秒前
12秒前
tuao234应助土豆不吃鱼采纳,获得20
12秒前
故意的迎松完成签到,获得积分10
13秒前
清爽的亦云完成签到,获得积分10
13秒前
善学以致用应助灯没点采纳,获得10
13秒前
14秒前
斯文谷秋发布了新的文献求助10
14秒前
15秒前
木之夏完成签到,获得积分20
15秒前
15秒前
面面发布了新的文献求助10
16秒前
Joker完成签到,获得积分0
16秒前
拼搏念蕾完成签到 ,获得积分20
17秒前
FashionBoy应助包子采纳,获得30
18秒前
星辰完成签到,获得积分20
18秒前
美琦完成签到,获得积分10
18秒前
kylin发布了新的文献求助10
19秒前
bkagyin应助小怪兽采纳,获得10
20秒前
Sue完成签到 ,获得积分10
20秒前
22秒前
碧蓝毛豆完成签到 ,获得积分10
22秒前
23秒前
快乐的幼丝完成签到 ,获得积分10
24秒前
高分求助中
Medicina di laboratorio. Logica e patologia clinica 600
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
Machine Learning for Polymer Informatics 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
2024 Medicinal Chemistry Reviews 480
Geochemistry, 2nd Edition 地球化学经典教科书第二版 401
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3216667
求助须知:如何正确求助?哪些是违规求助? 2865899
关于积分的说明 8149397
捐赠科研通 2532374
什么是DOI,文献DOI怎么找? 1365742
科研通“疑难数据库(出版商)”最低求助积分说明 644601
邀请新用户注册赠送积分活动 617511